TTBK1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL168084	1.00	16/20
SCHEMBL1230553	0.54	11/20
SCHEMBL1230817	0.54	11/20
SCHEMBL1230845	0.51	11/20
SCHEMBL1934806	0.56	10/20
SCHEMBL1230493	0.54	10/20
SCHEMBL1717446	0.53	9/20
SCHEMBL1819928	0.52	8/20
SCHEMBL1046996	0.52	8/20
SCHEMBL1231369	0.48	8/20
SCHEMBL1229660	0.46	8/20
SCHEMBL1613847	0.72	7/20
SCHEMBL859117	0.64	7/20
SCHEMBL1095786	0.55	7/20
SCHEMBL102201	0.54	7/20
SCHEMBL1095638	0.54	7/20
SCHEMBL191691	0.51	7/20
SCHEMBL1229675	0.50	7/20
SCHEMBL191323	0.44	7/20
SCHEMBL1824960	0.44	7/20

Clinical trials — most relevant to TTBK1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Lithium for Prevention of Cognitive Declining in Mood Illnesses	PHASE4	NOT_YET_RECRUITING
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING
Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer	PHASE3	COMPLETED
Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer	PHASE3	SUSPENDED
A Multicenter Study of NAP (AL-108) in Schizophrenia	PHASE2	COMPLETED
Biologic Correlative Taxotere/AC	PHASE2	COMPLETED
Vit D and Peripheral Neuropathy in Taxane Naive Patients	PHASE2	UNKNOWN
TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC)	PHASE1/PHASE2	RECRUITING
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer	PHASE2	UNKNOWN
A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Study of ABT-751 in Patients With Refractory Hematologic Malignancies	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Safety Study of TPI-287 to Treat CBS and PSP	PHASE1	COMPLETED
Alzheimer's PET Imaging in Racially/Ethnically Diverse Adults	PHASE1	COMPLETED
Far Infrared Irradiation for the Management, Control and Treatment of Frontotemporal Dementia	PHASE1	UNKNOWN
Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease.	PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Generating Intervals of Reference FFor Early Life Brain Biomarkers.	nan	RECRUITING
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors	nan	ACTIVE_NOT_RECRUITING
Evaluation of a Novel PET Radioligand to Image OGA	nan	COMPLETED
A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib	nan	COMPLETED
Prodromal Model of Parkinson's Disease Confined to The Peripheral Nervous System	nan	ENROLLING_BY_INVITATION
Natural History Characterization in Symptomatic and Asymptomatic Progranuline Gene Mutation Carriers	nan	COMPLETED
Importance of the Microtubule Cytoskeleton in Oocyte Competence	nan	COMPLETED
Myotubular Myopathy Genetic Testing Study	nan	COMPLETED
Correlation Between EGFR Mutation Using cfDNAs and Circulating Tumor Cells in Patients With NSCLC	nan	UNKNOWN
Rostock International Parkinson's Disease Study (ROPAD)	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Disclosing Dementia Risk Based on Plasma Phosphorylated Tau	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a TTBK1 binder may also engage these)

Protein	Name	Similarity
Q6PCN3	—	1.000	Q6PCN3 →
Q640N3	—	0.994	Q640N3 →
Q3UIZ8	—	0.994	Q3UIZ8 →
EHMT1	Histone-lysine N-methyltransferase EHMT1	0.994	landscape →
Q96PX1	—	0.993	Q96PX1 →
E9Q9W7	—	0.993	E9Q9W7 →
Q9H329	—	0.992	Q9H329 →
Q9Z0Y7	—	0.992	Q9Z0Y7 →
Q8BG36	—	0.991	Q8BG36 →
Q8N5Z5	—	0.991	Q8N5Z5 →
Q9QX96	—	0.991	Q9QX96 →
Q3V1D5	—	0.991	Q3V1D5 →
Q9H5P4	—	0.991	Q9H5P4 →
Q2PFD7	—	0.991	Q2PFD7 →
Q8VDU5	—	0.991	Q8VDU5 →
Q86V15	—	0.990	Q86V15 →
Q00175	—	0.990	Q00175 →
A0JMD2	—	0.990	A0JMD2 →
P11299	—	0.990	P11299 →
Q76N89	—	0.990	Q76N89 →
Q2M1Z3	—	0.990	Q2M1Z3 →
Q8IZ21	—	0.990	Q8IZ21 →
Q9Z148	—	0.990	Q9Z148 →
Q5R8Z4	—	0.990	Q5R8Z4 →
Q60700	—	0.990	Q60700 →
Q5XIX0	—	0.990	Q5XIX0 →
Q9JIH7	—	0.990	Q9JIH7 →
Q9HCH5	—	0.990	Q9HCH5 →
O54963	—	0.990	O54963 →
Q80YR5	—	0.990	Q80YR5 →